Your session is about to expire
← Back to Search
Cannabinoid
Cannabidiol for Anxiety Disorders
Phase < 1
Waitlist Available
Research Sponsored by University of Connecticut
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* 18-50 years of age
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 20 minutes
Summary
This trial will test if CBD can help college students with social anxiety overcome their fear. Participants will be conditioned to fear a face followed by a shock, then half will take CBD while the other half takes
Who is the study for?
This trial is for college undergraduates aged 18-50 at the University of Connecticut who show high levels of social anxiety. Participants must not have any conditions that would exclude them from safely receiving CBD or a placebo.
What is being tested?
The study tests if a single dose of Cannabidiol (CBD) can help reduce fear and anxiety compared to a placebo. It measures how participants respond to faces associated with mild shocks after taking either CBD or a sugar pill, without further shocks.
What are the potential side effects?
Potential side effects of CBD include tiredness, diarrhea, changes in appetite/weight, and possibly affecting liver enzymes. The placebo should have no active effects but may cause reactions based on belief it's real.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 20 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~20 minutes
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Electrodermal activity
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: CannabidiolExperimental Treatment1 Intervention
600 mg Cannabidiol Isolate Gel Capsules / participant. One-time dose.
Group II: PlaceboPlacebo Group1 Intervention
Same number of placebo capsules / participant. One-time dose.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cannabidiol Oral Product
2020
Completed Phase 4
~90
Find a Location
Who is running the clinical trial?
University of ConnecticutLead Sponsor
189 Previous Clinical Trials
160,688 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger